#BioTheryX
LightNews LightNews
manalmehta.bsky.social
This is a very interesting financing for those who follow #MolecularGlues #TPD #TargetedProteinDegradation round by #BioTheryX. @jaybradner @HartungIngo @MilkaKostic @elkingtonxy @ChemGenetics @CrisMayorRuiz @CraigMCrews
November 19, 2024 at 2:05 PM
newsen.bsky.social
Biotheryx's BTX-9341: A New Hope for Advanced Breast Cancer Treatment#United_States#San_Diego#Breast_Cancer#Biotheryx#BTX-9341
Biotheryx's BTX-9341: A New Hope for Advanced Breast Cancer Treatment
Biotheryx has released promising data on BTX-9341, a novel treatment for HR+/HER2- breast cancer, showcasing safety and early clinical activity.
third-news.com
May 18, 2026 at 12:32 PM
newsen.bsky.social
Biotheryx to Showcase Promising Results of BTX-9341 for HR+/HER2- Breast Cancer at ESMO 2026#Germany#Berlin#Biotheryx#BTX-9341#ESMO_2026
Biotheryx to Showcase Promising Results of BTX-9341 for HR+/HER2- Breast Cancer at ESMO 2026
Biotheryx Inc. will present groundbreaking findings from the Phase 1A study of BTX-9341 for HR+/HER2- breast cancer at ESMO 2026, highlighting potential breakthroughs in treatment.
third-news.com
May 4, 2026 at 12:32 PM
newsen.bsky.social
Biotheryx Takes Significant Step Forward in Breast Cancer Treatment with BTX-9341-101 Trial#United_States#San_Diego#Cancer_Research#Biotheryx#BTX-9341
Biotheryx Takes Significant Step Forward in Breast Cancer Treatment with BTX-9341-101 Trial
Biotheryx, Inc. has commenced the dose expansion phase of its clinical trial for BTX-9341-101, targeting HR+/HER2- breast cancer. The focus is on enhancing treatment options for patients.
third-news.com
March 18, 2026 at 12:35 PM
newsen.bsky.social
Biotheryx Completes Enrollment for BTX-9341 Phase 1a Trial Targeting HR+/HER2- Breast Cancer#United_States#San_Diego#Breast_Cancer#Biotheryx#BTX-9341
Biotheryx Completes Enrollment for BTX-9341 Phase 1a Trial Targeting HR+/HER2- Breast Cancer
Biotheryx has successfully completed patient enrollment for its Phase 1a clinical trial of BTX-9341. This innovative treatment aims to improve outcomes for HR+/HER2- breast cancer patients.
third-news.com
November 17, 2025 at 1:40 PM
biotechnetworks.bsky.social
SDBN Trending: Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer https://zpr.io/hEYPLPZRu5XM
November 18, 2025 at 10:09 AM
l2plabs.bsky.social
Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer
SAN DIEGO, May 18, 2026 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced the data from its first-in-human Phase 1 Dose Escalation study evaluating...
dlvr.it
May 18, 2026 at 11:58 AM
l2plabs.bsky.social
Biotheryx to Present Results from its Phase 1A Dose Escalation Study of BTX-9341 for the Treatment of HR+/HER2- Breast Cancer at the 2026 European Society for Medical Oncology Breast Cancer Annual Congress
SAN DIEGO, May 4, 2026 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that data from its Phase 1A Dose Escalation Study of BTX-9341, a potent...
dlvr.it
May 4, 2026 at 11:59 AM
l2plabs.bsky.social
Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer
Topline data readout from Phase 1a clinical trial expected in Q1 2026 SAN DIEGO, Nov. 17, 2025 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced...
dlvr.it
November 17, 2025 at 1:08 PM